East Ocyon Bio, a startup focused on cell and gene therapy, has successfully raised $4.2 million in a seed funding round led by Aeravti and Micro Labs. The funding will be allocated towards pre-clinical testing of CAR-NK and CAR-gamma delta T cell therapies, the establishment of a Good Manufacturing Practice (GMP) manufacturing facility, and the initiation of Phase I clinical trials. In other developments in the biotech sector, Relay Therapeutics has announced updated interim data for its RLY-2608 treatment combined with Fulvestrant, indicating continued improvement in progression-free survival. Candel Therapeutics reported that its CAN-2409 treatment achieved the primary endpoint in a Phase 3 prostate cancer trial, demonstrating significantly improved disease-free survival. Additionally, Monte Rosa Therapeutics presented preclinical data at the 2024 San Antonio Breast Cancer Symposium regarding its CDK2-directed molecular glue degraders for treating HR-positive/HER2-negative breast cancer. Other notable mentions include Celcuity's presentation of overall survival data from a Phase 1b study of Gedatolisib in combination with Palbociclib and endocrine therapy, and positive initial data from ADC Therapeutics' LOTIS-7 trial evaluating ZYNLONTA in combination with Glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma.